FTC to change reporting rules for biotech license deals

The U.S. Federal Trade Commission (FTC) is seeking comments on a proposed rule that would require biotech and pharma companies to report all "commercially significant" patent licensing deals to the FTC and Department of Justice for antitrust review. According to an FTC spokesperson, the change would be a "significant" revision to reporting requirements and lead to an estimated 30 additional filings per year. ...